BioPharma Dive October 3, 2024
The agency will offer earlier meetings with drugmakers as well as solicit more patient feedback on the process.
The U.S. government is fine-tuning the rules for how it will negotiate drug prices within Medicare when the second round of talks with drugmakers begins early next year.
Specifically, officials at the Centers for Medicare and Medicaid Services plan to offer manufacturers earlier meetings to discuss pricing offers, according to final guidance the agency released Wednesday.
The tweaks also add further opportunities for patients, advocacy groups and caregivers to provide input on their experience with the drugs Medicare selects for negotiation, including a town hall intended to involve practicing physicians.
“Today’s final guidance for the Medicare Drug Price Negotiation Program builds off...
Today's Sponsors
Today's Sponsor